Contact Us
Subscribe
e-Edition

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

80° Partly Cloudy
- Plymouth, IN (46563)
  Today
  
  Thunderstorms during the evening will give way to cloudy skies after midnight. Low 63F. Winds NNE at 5 to 10 mph. Chance of rain 80%..
  
  Tonight
  
  Thunderstorms during the evening will give way to cloudy skies after midnight. Low 63F. Winds NNE at 5 to 10 mph. Chance of rain 80%.
  
  Updated: September 17, 2026 @ 6:22 pm
- Full Forecast

Site search

News
- Local News
- The Leader
Sports
Obituaries
Classifieds
Archives
Best of 2026
Pilot News E-Edition
Culver Citizen

Recent Quotes

View Full List

My Watchlist

Create Watchlist

Indicators

Dow Jones Industrial Average

Markets:

Overview

News

Currencies

International

Treasuries

ProMIS Neurosciences Inc. - Common Shares (NQ:PMN)

3.240 -0.170 (-4.99%)

Delayed Quote Updated: 2:30 PM EST, Nov 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ProMIS Neurosciences Inc. - Common Shares

< Previous 1 2 3 4 5 6 Next >

ProMIS Neurosciences Announces First Quarter 2025 Financial Results

May 12, 2025

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

March 31, 2025

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference

March 24, 2025

Multiple datasets support continued development of ProMIS’ antibody therapeutics and vaccines that selectively target toxic misfolded proteins to treat neurodegenerative diseases

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting

March 13, 2025

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences to Participate in the 37th Annual Roth Conference

March 11, 2025

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease

February 25, 2025

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference

January 29, 2025

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences Issues Letter to Shareholders

January 13, 2025

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer’s Disease

January 10, 2025

Targeting toxic oligomers without binding to plaque, designed to reduce the risk of ARIA and potentially deliver enhanced outcomes for patients

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference

November 26, 2024

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights

November 14, 2024

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference

November 12, 2024

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference

October 30, 2024

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences And 2 Other Stocks Under $5 Executives Are Buying ↗

September 19, 2024

Via Benzinga

Why Exicure Shares Are Trading Higher By Around 180%; Here Are 20 Stocks Moving Premarket ↗

September 19, 2024

Via Benzinga

ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences

September 12, 2024

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

September 05, 2024

From ProMIS Neurosciences Inc.

Via GlobeNewswire

Around $2M Bet On This Health Care Stock? Check Out These 3 Stocks Under $5 Insiders Are Aggressively Buying ↗

August 19, 2024

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

August 12, 2024

It's time to dive into the biggest pre-market stock movers for Monday morning with all of the latest news affecting shares today!

Via InvestorPlace

Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket ↗

August 12, 2024

Via Benzinga

PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q2 2024 ↗

August 08, 2024

PMN stock results show that ProMIS Neurosciences beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights

August 08, 2024

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology

August 06, 2024

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024

August 01, 2024

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference

July 30, 2024

From ProMIS Neurosciences Inc.

Via GlobeNewswire

Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

July 26, 2024

Via Benzinga

ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

July 26, 2024

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing

July 26, 2024

From ProMIS Neurosciences Inc.

Via GlobeNewswire

PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q1 2024 ↗

May 15, 2024

PMN stock results show that ProMIS Neurosciences beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

May 14, 2024

Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024

From ProMIS Neurosciences Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

News
Sports
Entertainment
Local Events
Obituaries
Multimedia
Announcements
Online Features

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Search
Weather

www.thepilotnews.com
218 N. Michigan
Plymouth, IN 46563
Phone: 574-936-3101
Email: webmaster@thepilotnews.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Plymouth, IN (46563)

Today

Tonight

ProMIS Neurosciences Inc. - Common Shares (NQ:PMN)

All News about ProMIS Neurosciences Inc. - Common Shares

Sections

Services